NASDAQ: XCURExicure Inc Stock
$1.29-0.12 (-8.51%)
Updated Aug 28, 2026
XCUR Price
$1.29
Fair Value Price
$0.57
Market Cap
$8.44M
52 Week Low
$1.05
52 Week High
$9.48
P/E
-0.98x
P/B
8.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
10.67
Operating Cash Flow
-$7M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XCUR Overview
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XCUR's potential to beat the market
- XCUR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XCUR
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.06 | A | |
| $113.88 | A | |
| $6.95 | A |
Be the first to know about important XCUR news, forecast changes, insider trades & much more!
XCUR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XCUR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XCUR ($1.29) is overvalued by 127.54% relative to our estimate of its Fair Value price of $0.57 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XCUR ($1.29) is not significantly undervalued (127.54%) relative to our estimate of its Fair Value price of $0.57 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XCUR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XCUR due diligence checks available for Premium users.
Valuation
XCUR fair value
Fair Value of XCUR stock based on Discounted Cash Flow (DCF)
Price
$1.29
Fair Value
$0.57
Overvalued by
127.54%
XCUR ($1.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XCUR ($1.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XCUR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XCUR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.98x
Industry
16.84x
Market
40.56x
XCUR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.64x
Industry
5.46x
XCUR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XCUR's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.1M
Profit Margin
0%
XCUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.4M
Liabilities
$10.4M
Debt to equity
10.67
XCUR's short-term liabilities ($4.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XCUR's long-term liabilities ($6.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XCUR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XCUR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$887.0k
Investing
$0.0
Financing
$0.0
XCUR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XCUR vs Biotech Stocks
Exicure Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.